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Abstract
Our quest to isolate and characterize natural products with in vitro solid tumor selectivity is driven 
by access to repositories of Indo-Pacific sponge extracts. In this project an extract of a species of 
Haplosclerida sponge obtained from the US NCI Natural Products Repository displayed, by in 
vitro disk diffusion assay (DDA) and IC50 determinations, selective cytotoxicity with modest 
potency to a human pancreatic cancer cell line (PANC-1) relative to the human lymphoblast 
leukemia cell line (CCRF-CEM). Two brominated indoles, the known 6-bromo conicamin (1) and 
the new derivative, 6-Br-8-keto-conicamin A (2), were identified and 2 (IC50 1.5 μM for the 
natural product vs 4.1 μM for the synthetic material) was determined to be responsible for the 
cytotoxic activity of the extract against the PANC-1 tumor cell line. The new natural product and 
ten additional analogs were prepared for further SAR testing.
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We believe that the study of bioactive natural products from sponges obtained within the 
Indonesian Coral Triangle, called by some the “biodiversity bullseye,” represents an 
underexplored, rich opportunity. One example of a significant result obtained from 
exploration of the region is that manzamine A, a complex sponge-derived antimalarial 
alkaloid1 (also a putative sponge-associated bacterial product)2 and subject of sustained 
investigation,3 can be isolated in large amounts from several Indonesian sponges. Motivated 
by this outcome, we continue to evaluate sponge extracts from repositories rich in 
Indonesian sponge taxa. Currently, these resources consist of: 558 alcohol preserved sponge 
samples collected by the UC Santa Cruz team, and 230 Indonesian marine sponge extracts 
provided to UCSC from the NCI-DTP repository.4 An important filter to prioritize work on 
these samples utilizes a primary in vitro disk diffusion assay (DDA) developed at the Henry 
Ford Cancer Institute. This assay flags samples based on selectivity and potency against five 
solid tumor cell lines (human pancreatic cancer PANC-1, human ovarian OVCAR-5, human 
lung H125, human hepatoma HepG2, and human brain U251N) compared to responses from 
two normal cell lines (murine and human hematopoietic progenitor cells, CFU-GM) and a 
leukemia cell line (CEM).5 The five cancers represented by these cell lines account for 74% 
of all solid tumor cancers (1,658,000 cases per year in the US) and 70% of solid tumor 
mortality (589,000 deaths per year in the US).6 The output from our primary screen is 
quantified by measuring the radius of cell death after exposure to extract or compounds, 
where selectivity is defined by a differential zone of inhibition between cell lines.
The first phase of our effort to evaluate the sample library described above has been to 
pinpoint extracts and compounds with solid tumor selectivity in the DDA5 (those with a > 
6.5 mm difference in zone of inhibition for solid tumor cell lines vs. either bone marrow 
progenitor or leukemia cells). During the last two years, 120 of the UCSC sponges along 
with 136 organic extracts of the NCI-DTP sponge samples have been extracted, pre-
fractionated, and tested. The overall priority hit rate is low (≅ 1%), but there have been a 
number of positive outcomes using this approach with Indonesian sponges, including our 
recently published finding that makaluvamine J can be isolated from both UCSC and DTP 
collections of Zyzzya fuliginosa. This compound exhibits solid tumor selectivity for both 
PANC-1 (IC50 = 54 nM) and OVCAR-5 (IC50 = 120 nM) cells.7 The general steps involved 
in the discovery process (Chart 1) have now been applied to the 256 samples in this 
assemblage and one chosen for detailed analysis has provided the results reported herein, 
while outcomes from the remaining sponge active extracts will be published elsewhere.
2. Results and discussion
The extract of Oceanapia sp. C011027 (from the NCI-DTP repository) was prioritized for 
investigation in this study using the soft agar disk diffusion assay (DDA) whose results are 
shown in Table 1. The DDA measures a zone of inhibition (in mm) for a sample diffusing 
from a disk placed at the edge of the petri dish containing tumor cells embedded in a soft 
agar matrix. Samples considered to have high cytotoxicity exhibit a zone of inhibition ≥ 20 
mm in any of the cell lines, which included five solid tumor cell lines, a leukemia line 
(CEM), and bone marrow progenitor cells (CFU-GM). Some benchmark results are 
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provided by the activities for two clinical drugs, gemcitabine and 5-fluorouracil, which are 
powerful cytotoxins against almost all of the eight cell lines screened. Both drugs also 
displayed selectivity between one or more solid tumor cell lines and either the leukemia or a 
normal cell surrogate (zone of inhibition difference > 7mm, indicated by bold numbers in 
Table 1). The best response for the Oceanapia sp. extract was against PANC-1 (zone of 
inhibition = 23 mm) which represented selective cytotoxicity relative to both CEM and 
murine CFU-GM cells (Δinhibition zone = 10 mm and 7 mm, respectively). These results 
prompted creation of an HPLC peak library that was screened in the DDA and the active 
fractions were further evaluated by MSn and NMR. Subsequent isolation afforded the known 
Suberites sponge compound, 6-Br-concamin (1)8 and an unreported compound 6-Br-8-keto-
concamin A (2) shown in Fig. 1. While 1 was not cytotoxic by the DDA, synthetic 2 (2a) at 
112 nmol/disk exhibited a zone of inhibition = 28 mm against PANC-1 and 33 mm against 
MCF-7, each with a greater than 20 mm differential between CEM and CFU-GM cell lines. 
We also synthesized a family of bromoindole compounds bearing quaternary ammonium 
substituents including the 5-Br analog of 2 (3), which was also active in the DDA with an 
inhibition zone of 20 mm against PANC-1 and 33 mm against MCF-7, again selective 
between these solid tumor cell lines and CEM and CFU-GM. Eight other synthetic 
intermediates employed in the syntheses were inactive in the DDA. Additional elements of 
the study included two comprehensive evaluations: (a) unraveling NMR δ values to facilitate 
the placement of a halogen at the 5 vs. 6 position of an indole ring, and (b) using the 
PANC-1 IC50’s to define a useful SAR pattern for this indole scaffold.
A DDA active fraction (data not shown herein) from the Oceanapia peak library actually 
contained a mixture of two compounds with m/z of 279 and 295, each having an M+2 peak 
of equivalent height, indicating the presence of a single bromine atom. The two compounds 
briefly discussed above, known 6-Br-conicamin (1)8 and new 6-Br-8-keto-conicamin (2), 
were separated by semi-preparative reversed phase HPLC using 21:89 acetonitrile:H2O. 
Neither fraction formed adducts in ESI mass spectrometry when spiked with sodium or 
potassium, consistent with a native positive charge. Accurate mass measurement gave two 
nearly identical molecular formulas differing by an oxygen: 1: ESI m/z 279.0467 [M]+ 
(calcd for C13H16N279Br, 279.0491) and 2: ESI m/z 295.0419 [M]+ (calcd for 
C13H16N2O79Br, 295.0441). The mass data from 1 coupled with a 1H NMR spectrum 
showing four indole ring protons, two vinyl protons and a singlet for nine protons near δ3 
allowed 1 to be identified as 6-bromo-conicamin (1) by dereplication. Despite the structural 
similarity implied by both MS and NMR data, the structure of 2 had not been reported in the 
literature. Inspection of the 13C NMR spectrum of 2 revealed that the vinyl carbons in 1 
were not present and were replaced by a ketone at δC 185.4 and a CH2 at δC 66.1, 
respectively (Table 1). The HMBC correlations observed from the N-trimethyl protons at δH 
3.33 to the CH2 at δC 66.1 but not the carbonyl at δC 185.4 suggested a ketone-methylene-
trimethylamine motif. These data coupled with the remaining long range correlations 
observed by gHMBCAD enabled provisional assignment of 2. However, placement of the Br 
at either C-5 or C-6 could not be confidently assigned. This ambiguity was resolved by 
additional NMR δ analyses discussed next along with NMR data comparison to synthesized 
products including 6-bromo-8-keto-conicamin A (2a), and 5-bromo-8-keto-conicamin A (3).
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Finalizing the Br atom placement in natural product 2 at C-5 vs. C-6 (Fig. 1) should be 
trivial as it involves assigning the relative position of an indole AB spin system as proximal 
or distant to the NH. Unfortunately, our attempts to obtain NOE or HMBC correlations to 
the NH residue for a definitive resolution were unsuccessful. Alternatively, a literature 
search to provide NMR δH and δC values distinctive for these isomeric frameworks provided 
diagnostic patterns shown in Figure 1. First, the δH shifts at H-4/H-5 (3JH-H portion), and 
H-7 for a 6-bromo isomer are different vs. those at H-4, and H-6/H-7 (3JH-H portion) for a 5-
bromo isomer as shown in Fig. 2. A key is that the relative ΔδH for the o-proton doublets is 
small (≅ 0.2 ppm) for the 5-Br isomer but large (> 0.5 ppm) for the 6-Br isomer. Second, the 
δC at C-3a is deshielded by approximately 3 ppm in the 5-Br relative to that of the 6-Br 
indole.9, 10 The observed patterns for 2 matched that of the lower example in Figure 2: 
vicinal proton ΔδH = 0.69 and δC-3a = 124.3. Correspondingly, the synthetic compounds 
obtained as described in the next section further supported these observations. For example, 
the spectrum of 3 matched that of the upper example in Figure 2: the vicinal proton ΔδH = 
0.20 and δC-3a = 127.7 (see NMR data in Table 1, supplemental Figs. S9 & S10), and the 
data of the commercially available aldehyde 5 matched that of the lower example in Figure 
2: the vicinal proton ΔδH = 0.67 and δC-3a = 123.1.
The process to obtain compound 2 and other analogs by synthesis is shown in Scheme 1. 
Two indole-3-carboxaldehydes, 4 and 5, were used as separate starting materials to provide 
the oxotryptamine synthons 10 and 11. While the yield of the cyanohydrin silylether 6 from 
4 match that in the literature (60%), the yield of 7 from 5 was poor (20%) vs that in the 
literature for the 5-Br analog (88%).11 Oxidation of both 6 and 7 via DDQ provided high 
yields of 8 (83%) and 9 (60%).11 Hydrogenation of 8 afforded 10 in good yield after workup 
(76%) and reduction of 9 provided the first route to 11.12 Bromination of the keto-
tryptamine synthon 10 proceeded in a straightforward fashion, producing the bromo-keto-
tryptamines 11 and 12 which were separated by reversed phase HPLC.13 We used 11 
prepared from 5 to confidently distinguish between the 5- and 6-bromo isomers (11 and 12) 
prepared via bromination of 10. NMR spectroscopic experiments on the commercially 
obtained 5 assured correct assignment (see SI figures S34–38). The final steps involved 
methylation of 10, 11, or 12 to respectively afford 13, 2a, or 3. Performing these reactions 
with a reduced molar ratio of methyl iodide provided the dimethyl analogs 14, 15, or 16 
from 11, 12, or 10, respectively as minor products. The compounds 2a, 11, or 14 were 
produced in duplicate from either 5 or 10 as starting material and were equivalent in their 
spectroscopic and bioassay properties.
The synthetic work to prepare 2 and its analogs provided additional information to probe the 
structure-activity relationship describing the cytotoxicity of Br-indoles. Based on our DDA 
and IC50 screening of the intermediates and products from the synthesis, only the 
compounds most similar to 2 (such as 3 and 13) possessed notable cytotoxic activity as 
shown in Tables 1 and 3. The DDA data (Table 1) indicates similar solid tumor selectivity 
for 2 and 3 in comparison to the two therapeutic standards. The IC50 data (Table 3) reveals 
that a quaternary amine functionality is vital for low uM activity against PANC-1 cells, 
which is on a par with that of the two therapeutic standards, 5-flourouracil and gemcitabine. 
Also, the presence of the Br atom at C-5 or C-6 on the indole ring and the keto group at C-8 
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are significant factors in the IC50 activity of 2 and 3. Interestingly, relative to 2, the primary 
amines (compound 10–12) and tertiary amines (compounds 14 – 16) were inactive in both 
the DDA and the IC50 determinations. In addition, 13, which lacks a Br, was not selective in 
the DDA screen and was an order of magnitude less potent vs. 2 against PANC-1 cells based 
on IC50 data. While the position of the Br (at C-5 or C-6) is less important, it was the 6-
bromo-8-keto-conicamin (2) that exhibited the best DDA selectivity for PANC-1 and 
MCF-7, and greatest potency against PANC-1 (IC50 data against MCF-7 were not 
measured). Overall, the low micromolar in vitro activity of 2 against the PANC-1 cell line 
(IC50 1.5 μM for the natural product vs 4.1 μM for the synthetic material) is exciting and is 
similar to that of the clinical therapeutics (5FU: IC50 = 7.0 μM; gemcitabine: IC50 = 0.02 
μM).
3. Conclusion
The halogenated indole moiety found in 2 has been observed in a number of metabolites 
from marine macro- and microorganisms, including the topsentins,9 aplysinopsins,10 
dragmacidins,16 hypaphorines,17 didemnimides,18 and nakijinamines.8 Thorough reviews of 
marine-derived indole alkaloids and their activities has been published elsewhere.19,20 The 
bioactivity of these compounds is diverse: cytotoxicity, antibacterial activity, anti-fungal 
activity, histamine receptor agonism, and neurotransmitter receptor affinity. The quaternary 
amine functionality found in 2 is rare, but there are examples of bioactive natural products 
containing this cationic residue attached to a halogenated indole scaffold (Fig. 3). A 
prenylated indole from a bryozoan with moderate nAChR activity prompted medicinal 
chemistry efforts in which some analogs (e.g. 18) attained high nanomolar affinity for a 
variety of nAChR subtypes.21 The results of this study are modest, yet the in vitro 
cytotoxicity of 2 against the PANC-1 cell line exceeds that reported for 5-FU and 
gemcitabine, which are the primary constituents of the current standards of care for 
pancreatic cancer.14, 15 The structure of 2 was confirmed by synthesis and a number of 
analogs were made using methodology originally developed for the syntheses of the 
rhopaladins, dragmacidins, and almazoles.11, 12, 13 The quaternary amine functionality and 
bromination of the indole ring of 2 was critical for activity against PANC-1. The new small 
molecule discovered in this work highlights the value of continued pursuit of achiral marine 
natural products and the effectiveness of continued screening using the NCI Developmental 
Therapeutics Program extract library. Overall, the lack of small molecule therapies to treat 
pancreatic cancer makes the results presented in Table 3 reasonably significant.
4. Experimental
4.1 General experimental procedures
UV spectra were measured with Thermo Ultimate 3000 DAD. IR spectra were measured 
with a Perkin-Elmer Spectrum One FTIR spectrometer. Analytical LC-MS analysis was 
performed on samples at a concentration of 10 mg/mL for crude extracts and 1 mg/mL for 
pure compounds, using a 150 × 4.60 mm 5 μm C18 Phenomenex Luna column in 
conjunction with a guard column and 4.0 × 3.0 mm C18 cartridge (Phenomenex, Inc.). 20 
uL volumes of sample were injected onto the column using Waters 717 autosampler, with a 
Lorig-Roach et al. Page 5













flow rate of 1 mL/min provided by two Waters 515 HPLC pumps. The eluent was split 
between an Applied Biosystems Mariner 5200 electrospray ionization time-of-flight (ESI-
TOF) mass spectrometer and a Waters 996 photodiode array (PDA) UV detector in line with 
a SEDERE 75 evaporative light scattering detector (ELSD). Optical rotations were 
performed on a JASCO P-2000 polarimeter; the average of 10 measurements is reported, 
each with 10 second digital integration time and 12 second cycle time. All NMR 
experiments were run on a Varian Unity spectrometer (500 and 125 MHz for 1H and 13C, 
respectively) or Varian INOVA spectrometer (600 and 150 MHz for 1H and 13C, 
respectively) equipped with a cryoprobe. High accuracy mass spectrometry measurements 
were recorded using an Applied Biosystems Mariner 5200 electrospray ionization time of 
flight (ESI-TOF) mass spectrometer. Synthetic procedures were either performed via 
Schlenk line with nitrogen or via balloon and septa techniques with argon. Flash 
chromatography was performed using a Biotage Isolera Prime fraction collector with a 100 g 
silica gel 60 column.
4.2. Biological material
The sponge Oceanapia sp. C011027 (phylum Porifera, class Demospongia, order 
Haplosclerida) was collected at 10 m depth off the coast of Sulawesi, Indonesia. Sample 
collection and identification was done by the Coral Reef Foundation under contract to the 
National Cancer Institute (National Institutes of Health). A taxonomic voucher specimen 
(number 0CDN1333) was deposited at the Smithsonian Institution in Suitland, MD (USA).
4.3. Compound isolation
After extract C011027 demonstrated solid tumor selective activity, an HPLC peak library 
was generated to determine the active constituents. The extract was fractionated using a 250 
× 10 mm Phenomonex Luna C18 5μm semi-preparative column equipped with an analytical 
guard column (4.0 × 3.0 mm C18 cartridge) and two Waters 515 HPLC pumps. The eluent 
was monitored by a Waters 996 detector before being fractionated by a Gilson 215 Liquid 
Handler that generated one fraction per minute. A Waters 717 autosampler injected 100 uL 
of extract at 70 mg/mL onto the column; the first gradient 10:90 acetonitrile:H2O was held 
for 1 minute, then linearly shifted to 100:0 acetonitrile:H2O over 29 minutes, and finally 
held at 100:0 acetonitrile:H2O for 10 minutes. Fractions H16 and H17 were the only 
fractions with significant zones of inhibition when evaluated in the DDA. These contained a 
mixture of 1 and 2. Compounds 1 and 2 were separated using the following isocratic 
conditions: 21:79 acetonitrile:H2O with tR = 12.5 and 15.5, respectively. Note that the 
charge of these compounds leads to significant tailing and inconsistent retention times over 
longer timescales (i.e. weeks). This can be mitigated to some extent by using TFA in the 
mobile phase. Fraction collection was done manually using the same column as above with 
two Waters 510 HPLC pumps, a Waters Model 680 gradient controller, and an ABI 
Analytical Spectroflow 783 UV detector monitoring at 230nm.
4.3.1. 6-bromo-conicamin (1)—HAESIMS m/z 279.04667 [M]+ (calcd for 
C13H16N279Br, 279.04914). NMR spectra were in accordance with literature.8
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4.3.2. 6-bromo-8-keto-conicamin (2)—Light pink crystalline solid; UV (MeCN:H2O) 
209, 247, 271, 308 nm; IR (film) υmax 3438, 3250, 1637, 1520, 1443, 1414, 1384, 1048, 
891, 595 cm−1; 1H NMR (DMSO-d6, 600 MHz) δ 8.58 (1H, bs, H-2), 8.08 (1H, d, J = 8.5 
Hz, H-4), 7.77 (1H, s, H-7), 7.39 (1H, dd, J = 1.3, 8.5 Hz, H-5), 4.99 (2H, s, H-1′), 3.33 
(9H, s, N-(CH3)3); 13C NMR (DMSO-d6, 150 MHz) δ 185.4 (C, C-2′), 138.1 (C, C-7a), 
136.9 (CH, C-2), 125.4 (CH, C-5), 124.3 (C, C-3a), 122.7 (CH, C-4), 115.9 (C, C-6), 115.6 
(CH, C-7), 114.6 (C, C-3), 66.1 (CH2, C-1′), 53.5 (CH3, N-(CH3)3); HAESIMS m/z 
295.04191 [M]+ (calcd for C13H16N2O79Br, 295.04405).
4.4.1. 2-(1H-indole-3-yl)-2-(trimethylsiloxy)acetonitrile (6)—Procedure adapted 
from Janosik.11 To a solution of 1.16g 1H-indol-3-yl-carboxaldehyde (Combi-Blocks, San 
Diego, CA, USA) in 10mL acetonitrile, 1.3 mL TMSCN was added. The reaction solution 
was heated and maintained at reflux for 2 h before cooling. After evaporation of the solvent, 
reaction products were purified from the resulting oil using flash chromatography (isocratic 
80:20 hexane-ethyl acetate) to afford 6 (1.2g, 65%) as a lime-green oil. MS (ESI) 243 m/z 
(M-H)−. NMR data were in accordance with literature.
4.4.2. 2-(6-bromo-1H-indol-3-yl)-2-(trimethylsiloxy)acetonitrile (7)—Adapted from 
procedure for 5-bromo isomer from Janosik.11 To a solution of 1.08g 6-bromo-1H-indol-3-
yl-carboxaldehyde (Tokyo Chemical Industry, Tokyo, Japan) in 10mL DME, 0.73 mL 
TMSCN was added. The reaction solution was heated and maintained at reflux for 2.5 h 
before cooling. After evaporation of the solvent, reaction products were purified by flash 
chromatography (hexane-ethyl acetate gradient) to afford 7 (0.35g, 19%) as a light yellow 
oil. 1H NMR (DMSO-d6, 600 MHz) δ11.45 (1H, S), 7.63 (1H, d, J = 1.9), 7.60 (1H, d, J = 
8.4), 7.56 (1H, d, J = 2.6), 7.24 (1H, dd, J = 8.5, 1.8), 6.18 (1H, s), −0.11 (9H, s); 13C NMR 
(DMSO-d6, 150 MHz) δ 137.4, 126.0, 123.8, 122.5, 120.4, 119.9, 114.7, 114.6, 111.0, 56.8, 
−0.23. MS (ESI) 321 and 323 m/z (M-H)−.
4.4.3. 1H-indol-3-carbonyl cyanide (8)—A solution of DDQ (1.21 g, 5.3 mmol) in 60 
mL dioxane was added dropwise by addition funnel to a stirring solution of 6 (1.18 g, 4.8 
mmol) in 10 mL dioxane. After 2.5 h the reaction mixture was filtered and the filtrate dried 
to a purple-black solid. Flash chromatography (DCM-EtOAc gradient) afforded 8 (0.68g, 
83%) as a yellow oil. MS (ESI) 171 m/z [M+H]+. NMR data were in accordance with 
literature.
4.4.4. 6-bromo-1H-indol-3-carbonyl cyanide (9)—The procedure above was used 
with 6-bromo-indole-TMS (7) (0.35g, 1.1 mmol) and DDQ (0.27g). Flash chromatography 
(hexanes-EtOAc gradient) afforded 9 (0.15g, 55%) as a fluffy yellow solid. MS (ESI) 
247/249 [M-H]−.
4.4.5. 8-keto-tryptamine (10)—To 150 mg of 10% Pd/C, a solution of 1 mmol of 1H-
indol-3-carbonyl cyanide (8) in 10 mL acetic acid was added. Hydrogen gas was added via 
balloon and septum. After 15 h, the reaction mixture was filtered using diatomaceous earth 
and the filtrate was dried, resuspended in water, basified, then extracted with ethyl acetate to 
give 0.76 mmol of the free base 10. NMR data were in accordance with literature.
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4.4.6. 6-bromo-8-keto-tryptamine (11)—The first route to 11 employed the procedure 
above (10) using 9 as starting material. The second route was performed as follows. To a 
stirring solution of β-keto-tryptamine (10) in 1:1 formic acid:acetic acid, 1.2 equivalents of 
Br2 was added dropwise. After 24 h, the reaction mixture was dried and subjected to 
reversed phase HPLC to afford 11 and 12. 1H NMR (DMSO, 500 MHz) δ 12.47 (1H, s, 
NH), 8.52 (1H, d, J = 3 Hz, H-2), 8.1 (1H, d J = 8.4 Hz, H-4), 7.74 (1H, s, H-7), 7.4 (1H, d J 
= 8.5 Hz, H-5), 4.38 (2H, s, H-9); 13C NMR (DMSO, 125 MHz) δ 187 (CO), 137.5, 136, 
123.3, 124.1, 122.6, 115.6, 115.8, 115.2, 113.1, 44.1. MS (ESI) 252/254 [M+H]+.
4.4.7. 5-bromo-8-keto-tryptamine (12)—The second procedure above for 11 also 
afforded 12 by reversed phase HPLC. 1H NMR (DMSO, 500 MHz) δ 8.54 (1H, d J=3.0 Hz, 
H-2), 8.29 (1H, d J = 1.8 Hz, H-4), 7.53 (1H, d J = 8.6 Hz, H-7), 7.41 (1H, dd J = 8.6, 1.7 
Hz, H-6), 4.39 (2H, s, H-9); 13C NMR (DMSO, 125 MHz) δ 187, 136.3, 135.4, 126.8, 
125.9, 123.0, 115.1, 114.7, 112.6, 44.1. MS (ESI) 252/254 [M+H]+.
4.4.8. 8-keto-N,N,N-trimethyltryptamine (13)—To a solution of 8-keto-tryptamine (10) 
in KHCO3-saturated MeOH, 3 equivalents of methyl iodide were added and stirred 
overnight. The product mixture under these conditions contained unreacted starting material 
(10), 13, 14, and a minor amount of the single methyl analog which were separated by 
reverse phase HPLC. Using excess MeI (> 5 eq) yields exclusively the quaternary amine 
product. Yellow solid; 1H NMR (DMSO 600 MHz) δ 8.51 (1H, s), 8.15 (1H, d J = 7.3 Hz), 
7.57 (1H, d J = 7.3 Hz), 7.24 (2H, m), 4.93 (2H, s), 3.32 (9H, s). 13C NMR (DMSO, 150 
MHz) δ 184.9, 137.4, 136.5, 125.4, 123.3, 122.4, 121.0, 114.6, 113.1, 66.05, 53.5. 
HAESIMS m/z 217.1327 [M+H]+ (cald for C13H17ON2, 217.1341)
4.4.9. 6-bromo-8-keto-conicamin (2a)—See above procedure for 13, but using 
compound 11 as starting material. The product mixture primarily contained 2a and 14, 
which were seprable by reverse phase HPLC. Off-white crystalline solid; 1H NMR (DMSO 
600 MHz) δ 8.51 (1H, s), 8.07 (1H, d J = 8.41 Hz), 7.78 (1H, s), 7.35 (1H, d J = 8.46 Hz), 
4.90 (2H s), 3.31 (9H, s). 13C NMR (DMSO, 150 MHz) δ 184.6, 139.5, 138.2, 125.0, 124.8, 
122.5, 116.1, 115.5, 114.5, 66.1, 53.5. HAESIMS m/z 295.0443 [M]+ (calcd for 
C13H16N2O79Br, 295.0441).
4.4.10. 5-bromo-8-keto-conicamin (3)—See above procedure for 13, but using 
compound 12 as starting material. The product mixture primarily contained 3 and 15. Off-
white crystalline solid; 1H NMR (DMSO 600 MHz) δ8.52 (1H, s), 8.27 (1H, s), 7.54 (1H, d, 
J = 8.3 Hz), 7.34 (1H, d, J = 8.0), 4.91 (2H, s), 3.32 (9H, s). 13C NMR (DMSO, 150 MHz) 
δ184.4, 138.8, 137.6, 127.7, 125.4, 123.0, 115.6, 114.8, 114.0, 66.0, 53.5. HAESIMS m/z 
295.0442 [M]+ (calcd for C13H16N2O79Br, 295.0441)
4.4.11. 6-bromo-8-keto-N,N-dimethyltryptamine (14)—See above procedure for 13, 
but using compound 11 as starting material. 1H NMR (DMSO 600 MHz) δ12.26 (1H, s), 
8.45 (1H, s), 8.10 (1H, d, J = 8.5 Hz), 7.68 (1H, s), 7.31 (1H, dd, J = 8.4, 1.4 Hz), 3.52 (2H, 
s), 2.26 (6H, s) 13C NMR (DMSO, 150 MHz) see supplemental Figs. S29 and S30. 
HAESIMS m/z 281.0285 [M+H]+ (calcd for C12H14N2O79Br, 281.0290)
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4.4.12. 5-bromo-8-keto-N,N-dimethyltryptamine (15)—See above procedure for 13, 
but using compound 12 as starting material. 1H NMR (DMSO 600 MHz) δ8.46 (1H, s), 8.30 
(1H, bs), 7.46 (1H, d, J = 8.6 Hz), 7.32 (1H, broad d, J = 8.6 Hz), 3.51 (2H, s), 2.26 (6H, s) 
13C NMR (DMSO, 150 MHz) see supplemental Figs. S32 and S33. HAESIMS m/z 
281.0287 [M+H]+ (calcd for C12H14N2O79Br, 281.0290)
4.4.13. 8-oxo-N,N-dimethyltryptamine (16)—See above procedure for 13. 1H NMR 
(DMSO 600 MHz) δ 11.98 (1H, s), 8.42 (1H, d, J = 2.7), 8.17 (1H, d, J = 7.9 Hz), 8.15 (1H, 
d J =7.29 Hz), 7.47 (1H, d, J = 7.7 Hz), 7.20 (1H, td, J = 7.7, 7.1, 1.5 Hz), 7.17 (1H, td, J = 
7.9, 7.0, 1.3 Hz), 3.52 (2H, s), 2.27 (6H, s). 13C NMR via HMBC (DMSO, 150 MHz) δ 
192.9, 136.2, 135.9, 125.6, 122.6, 121.6, 121.3, 115.0, 112.1, 66.4, 45.4. HAESIMS m/z 
203.1179 [M+H]+ (cald for C12H15ON2, 203.1184)
4.5. Cytotoxic assays
Extract C011027 was evaluated in the in vitro disk diffusion soft agar colony formation 
assay which defines differential cell killing among 13 cell types. The screen includes CCRF-
CEM (leukemia), H125 (lung cancer), OVCAR-5 (ovarian cancer), MCF-7 (breast cancer), 
PANC-1 (pancreatic cancer), U251N (brain cancer), as well as a normal murine 
hematopoietic progenitor cell, CFU-GM. The human cancer cell lines are maintained in cell 
culture in either Dulbecco’s modified MEM, Eagles MEM or RPMI-1640 depending upon 
the cell lines. The media is supplemented with either 10% or 15% BCS plus Pen-Strept 
(100,000 I.U. Pen/L; 100,000 μg/L Strept) and L-glutamine (292 mg/L). Cells are removed 
from cultures by a trypsin solution (0.05%). Plating efficiencies are sufficiently high that 
30,000 to 60,000 cells in 3 mL produce the desired number of colonies (over 10,000 per 
plate) in 60 mm plates. This soft agar top layer (0.3% with the serum and media as above) 
plus the titrated tumor cells are poured into plates and allowed to solidify. A volume of 15 
μL of each sample is dropped onto a 6.5 mm disk (Whatman filter disks). The disk is 
allowed to dry overnight and then placed close to the edge of the petri dish. The plates are 
incubated for 7–10 days (depending upon cell type) and examined by an inverted stereo-
microscope (10×) for measurement of the zone of inhibition measured from the edge of the 
filter disk to the beginning of normal-sized colony formation. The diameter of the filter disk, 
6.5 mm, and a difference in zones between solid tumor cells and either normal or leukemia 
cells of 6.5 mm or greater defines solid tumor selective compounds. If the test material is 
excessively toxic at the first dosage, a range of dilutions of the agents (at 1:4 decrements) are 
tested against the same tumors. At some dilution, quantifiable cytotoxicity is invariably 
obtained.
IC50 assays were performed as follows. PANC-1 human pancreatic cancer (epithelioid 
carcinoma) cells are plated at 5×104 cells in T25 tissue culture flasks (Falcon Plastics, New 
Jersey) with 5 mL media RPMI 1640 (Cellgro, Virginia) supplemented with 15% BCS 
(Hyclone, Utah), 1% Penicillin-Streptomycin, and 1% Glutamine (Cellgro). Three days later 
(cells in logarithmic growth phase), test compounds are added to the flasks to achieve 
concentrations ranging from 100 to 10−5 μg/mL (10-fold dilutions). Seventy-two hours later, 
the cells in the flasks are washed, trypsinized, spun down and counted for both viable and 
dead cells using 0.04% trypan blue (Gibco, Maryland). Viable cell number as a function of 
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concentration is plotted and the IC50 value determined by interpolation. Each point is done 
in duplicate and a standard deviation determined. A second, definitive run is then carried out 
with four two-fold drug dilutions around the initial IC50 value and these are the IC50 values 
reported in Table 2.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The major products, 1 and 2, isolated from Oceanapia sp. C011027 and the 5-Br synthetic 
analog 3.
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Using NMR data to rapidly distinguish between 5- vs. 6-Br indole frameworks when the 
diagnostic NOEs to the NH cannot be observed. aThis work; bSeagraves;10 cBartik.9
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Other natural products featuring halogenated indole with a quaternary amine moiety.
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Synthesis of the natural product 6-Br-8-keto-conicamin (2a) and nine key analogs 3, 8, and 
10–16 for in vitro cytotoxicity screening against the PANC-1 tumor cell line. Following the 
synthetic route to 11 from 5 enabled facile differentiation between the 5- and 6-bromo 
isomers 11 and 12 synthesized from 10. The spectral and biological properties of 2a, 11, or 
14 derived from 5 were equivalent to those derived from 10.
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Overview of the campaign involving: sample acquisition, extraction, prefractionation, and 
Disk Diffusion Assay (DDA) for solid tumor selectivity against five human tumor cell lines. 
The work flow also involved dereplication and structure elucidation by accurate MSn and 
NMR spectroscopy along with SAR biological evaluation of natural products and synthetic 
analogues.
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Table 3
In vitro IC50 values against the PANC-1 cell line for natural 2, synthetic 2a, other synthetic analogs, and two 
therapeutic standards.
Compound PANC-1 IC50 (μM)
6-Br-conicamin (1) NA
6-Br-8-keto-conicamin A (2) [natural product] 1.5
6-Br-8-keto-conicamin A (2a) [synthetic product] 4.1
5-Br-8-keto-conicamin A (3) 5.8










NA – compounds inactive in soft-agar disk diffusion assay as shown in Table 1
*
Note that this IC50 was determined after 5 days compared to 48 hr. We have found in our lab (unpublished data) that there is ~250-fold difference 
in IC50 values between a 24 hr and a 5-day assay for gemcitabine.
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